Significance of Polymorphism in 2’,5’-Oligoadenylate Synthetase Genes in HIV Infection

The aim of the investigation was to assess the prognostic value of polymorphism of genes encoding 2’,5’-oligoadenylate synthetase (OAS) synthesis in HIV infection.

Materials and Methods. The DNA of 94 HIV infected patients have been sequenced using multiplex polymerase chain reaction. For molecular genetic testing we used DNA samples isolated from the scraping of oral epithelial cells. We studied interferon-induced genes, namely: OAS enzyme. It was a case–control study. Depending on the decrease rate of CD4-lymphocytes, the patients were divided into two groups: with typical disease progression and those with slow progression. We determined the frequencies of mutant alleles and genotypes in patients with different progression rates, and assessed genotype associations with different outcomes.

Results. There have been found oligonucleotide polymorphisms of OAS genes of different enzyme forms: OAS2 rs2072137 (chr12:113440921) and OAS3 rs1859330 (chr12:113376388). The frequency of mutant allele C of OAS2 rs2072137 polymorphism appeared to be significantly higher in a group with a typical disease progression (p=0.03). The frequency of mutant allele А of OAS3 rs1859330 polymorphism had no difference in the groups. In a group with mutant genotypes ТС and СС of OAS2 rs2072137 polymorphism, the frequency of typical disease progression was significantly higher than that in the group with the main (“wild”) genotype ТТ (p=0.0125). Logistic regression revealed typical HIV infection progression in patients to be significantly associated with OAS2 rs2072137 polymorphism and age.

Conclusion. OAS2 rs2072137 polymorphism is associated with typical progressive HIV infection, and, probably, presents a new genetic prognostic marker of the disease.

1. Samuel C.E. Antiviral actions of interferons. Clin Microbiol Rev 2001; 14(4): 778–809, http://dx.doi.org/10.1128/CMR.14.4.778-809.2001.
2. Honda K., Takaoka A., Taniguchi T. Type I interferon gene induction by the interferon regulatory factor family of transcription factors. Immunity 2006; 25(3): 349–360, http://dx.doi.org/10.1016/j.immuni.2006.08.009.
3. Lombardi V.C., Khaiboullina S.F. Plasmacytoid dendritic cells of the gut: relevance to immunity and pathology. Clin Immunol 2014; 153(1): 165–177, http://dx.doi.org/10.1016/j.clim.2014.04.007.
4. Sivro A., Su R., Plummer F., Ball T.B. Interferon responses in HIV infection: from protection to disease. AIDS Rev 2014; 16(1): 43–51.
5. Sheppard P., Kindsvogel W., Xu W., Henderson K., Schlutsmeyer S., Whitmore T.E., Kuestner R., Garrigues U., Birks C., Roraback J., Ostrander C., Dong D., Shin J., Presnell S., Fox B., Haldeman B., Cooper E., Taft D., Gilbert T., Grant F.J., Tackett M., Krivan W., McKnight G., Clegg C., Foster D., Klucher K.M. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 2002; 4(1): 63–68, http://dx.doi.org/10.1038/ni873.
6. González-Navajas J., Lee J., David M., Raz E. Immunomodulatory functions of type I interferons. Nat Rev Immunol 2012; 12(2): 125–135, http://dx.doi.org/10.1038/nri3133.
7. Bonnevie-Nielsen V., Field L.L., Lu S., Zheng D.J., Li M., Martensen P.M., Nielsen T.B., Beck-Nielsen H., Lau Y.L., Pociot F. Variation in antiviral 2’,5’-oligoadenylate synthetase (2’5’AS) enzyme activity is controlled by a single-nucleotide polymorphism at a splice-acceptor site in the OAS1 gene. Am J Hum Genet 2005; 76(4): 623–633, http://dx.doi.org/10.1086/429391.
8. Hornung V., Hartmann R., Ablasser A., Hopfner K.P. OAS proteins and cGAS: unifying concepts in sensing and responding to cytosolic nucleic acids. Nat Rev Immunol 2014; 14(8): 521–528, http://dx.doi.org/10.1038/nri3719.
9. Knapp S., Yee L.J., Frodsham A.J., Hennig B.J., Hellier S., Zhang L., Wright M., Chiaramonte M., Graves M., Thomas H.C., Hill A.V., Thursz M.R. Polymorphisms in interferon-induced genes and the outcome of hepatitis C virus infection: roles of MxA, OAS-1 and PKR. Genes Immun 2003; 4(6): 411–419, http://dx.doi.org/10.1038/sj.gene.6363984.
10. Imran M., Manzoor S., Khattak N.M., Tariq M., Khalid M., Javed F., Bhatti S. Correlation of OAS1 gene polymorphism at exon 7 splice accepter site with interferon-based therapy of HCV infection in Pakistan. Viral Immunol 2014; 27(3): 105–111, http://dx.doi.org/10.1089/vim.2013.0107.
11. Alagarasu K., Honap T., Damle I.M., Mulay A.P., Shah P.S., Cecilia D. Polymorphisms in the oligoadenylate synthetase gene cluster and its association with clinical outcomes of dengue virus infection. Infect Genet Evol 2013; 14: 390–395, http://dx.doi.org/10.1016/j.meegid.2012.12.021.
12. Barkhash A.V., Perelygin A.A., Babenko V.N., Myasnikova N.G., Pilipenko P.I., Romaschenko A.G., Voevoda M.I., Brinton M.A. Variability in the 2’-5’-oligoadenylate synthetase gene cluster is associated with human predisposition to tick-borne encephalitis virus-induced disease. J Infect Dis 2010; 202(12): 1813–1818, http://dx.doi.org/10.1086/657418.
13. Lim J.K., Lisco A., McDermott D.H., Huynh L., Ward J.M., Johnson B., Johnson H., Pape J., Foster G.A., Krysztof D., Follmann D., Stramer S.L., Margolis L.B., Murphy P.M. Genetic variation in OAS1 is a risk factor for initial infection with West Nile virus in man. PLoS Pathog 2009; 5(2): e1000321, http://dx.doi.org/10.1371/journal.ppat.1000321.
14. Vendrame D., Sourisseau M., Perrin V., Schwartz O., Mammano F. Partial inhibition of human immunodeficiency virus replication by type I interferons: impact of cell-to-cell viral transfer. J Virol 2009; 83(20): 10527–10537, http://dx.doi.org/10.1128/JVI.01235-09.
15. Rojas-Araya B., Ohlmann T., Soto-Rifo R. Translational control of the HIV unspliced genomic RNA. Viruses 2015; 7(8): 4326–4351, http://dx.doi.org/10.3390/v7082822.
16. Dimitrova D.I., Reichenbach N.L., Yang X., Pfleiderer W., Charubala R., Gaughan J.P., Suh B., Henderson E.E., Suhadolnik R.J., Rogers T.J. Inhibition of HIV type 1 replication in CD4+ and CD14+ cells purified from HIV type 1-infected individuals by the 2-5A agonist immunomodulator, 2-5AN6B. AIDS Res Hum Retroviruses 2007; 23(1): 123–134, http://dx.doi.org/10.1089/aid.2005.0091.
17. Bisbal C., Silhol M., Laubenthal H., Kaluza T., Carnac G., Milligan L., Le Roy F., Salehzada T. The 2’-5’ oligoadenylate/RNase L/RNase L inhibitor pathway regulates both MyoD mRNA stability and muscle cell differentiation. Mol Cell Biol 2000; 20(14): 4959–4969, http://dx.doi.org/10.1128/mcb.20.14.4959-4969.2000.
18. Molinaro R.J., Jha B.K., Malathi K., Varambally S., Chinnaiyan A.M., Silverman R.H. Selection and cloning of poly(rC)-binding protein 2 and Raf kinase inhibitor protein RNA activators of 2’,5’-oligoadenylate synthetase from prostate cancer cells. Nucleic Acids Research 2006; 34(22): 6684–6695, http://dx.doi.org/10.1093/nar/gkl968.
19. Bartlett D., Gallant D., Fam P. Klinicheskie aspekty VICh-infektsii [Medical management of HIV infection]. Moscow: R. Valent; 2012; 528 p.
20. Pokrovskiy V.V., Yurin O.G., Kravchenko A.V., Belyaeva V.V., Kanestri V.G., Afonina L.Yu., Ermak T.N., Buravtsova E.V., Shakhgil'dyan V.I., Kozyrina N.V., Narsiya R.S., Zimina V.E., Pokrovskaya A.V., Konov D.S., Konov V.V., Goliusova M.A., Efremova O.S. Protocols of follow up and treatment of patients with HIV infection. Epidemiologiya i infektsionnye bolezni 2012; S6: 1–28.
21. Langmead B., Salzberg S.L. Fast gapped-read alignment with Bowtie 2. Nat Methods 2012; 9(4): 357–359, http://dx.doi.org/10.1038/nmeth.1923.
22. Li H., Handsaker B., Wysoker A., Fennell T., Ruan J., Homer N., Marth G., Abecasis G., Durbin R.; 1000 Genome Project Data Processing Subgroup. The sequence alignment/map format and SAMtools. Bioinformatics 2009; 25(16): 2078–2079, http://dx.doi.org/10.1093/bioinformatics/btp352.
23. Reference SNP (refSNP) Cluster Report: rs2072137. URL: http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=2072137.
24. Reference SNP (refSNP) Cluster Report: rs1859330. URL: http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=1859330#map.
25. Mogensen T.H., Melchjorsen J., Larsen C.S., Paludan S.R. Innate immune recognition and activation during HIV infection. Retrovirology 2010; 7: 54, http://dx.doi.org/10.1186/1742-4690-7-54.
26. Sakuma R., Mael A.A., Ikeda Y. Alpha interferon enhances TRIM5α-mediated antiviral activities in human and rhesus monkey cells. J Virol 2007; 81(18): 10201–10206, http://dx.doi.org/10.1128/JVI.00419-07.
27. Piacentini L., Biasin M., Fenizia C., Clerici M. Genetic correlates of protection against HIV infection: the ally within. J Intern Med 2009; 265(1): 110–124, http://dx.doi.org/10.1111/j.1365-2796.2008.02041.x.
28. Chatterjee K. Host genetic factors in susceptibility to HIV-1 infection and progression to AIDS. J Genet 2010; 89(1): 109–116, http://dx.doi.org/10.1007/s12041-010-0003-4.
29. Migueles S.A., Sabbaghian M.S., Shupert W.L., Bettinotti M.P., Marincola F.M., Martino L., Hallahan C.W., Selig S.M., Schwartz D., Sullivan J., Connors M. HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc Natl Acad Sci USA 2000; 97(6): 2709–2714, http://dx.doi.org/10.1073/pnas.050567397.
30. Bartlett J.G. Factors affecting HIV progression. 2015. URL: http://www.uptodate.com/contents/factors-affecting-hiv-progression.
31. Langford S., Ananworanich J., Cooper D. Predictors of disease progression in HIV infection: a review. AIDS Res Ther 2007; 4: 11–25, http://dx.doi.org/10.1186/1742-6405-4-11.

Bakhteeva L.B., Khaibullina S.F., Lombardi V.K., Anokhin V.А., Rizvanov А.А., Boichuk S.V., Nagimova F.I. Significance of Polymorphism in 2’,5’-Oligoadenylate Synthetase Genes in HIV Infection. Sovremennye tehnologii v medicine 2016; 8(1): 99, https://doi.org/10.17691/stm2016.8.1.13